Capricor Therapeutics Shares Upcoming Q3 2025 Financial Insights
SAN DIEGO, Capricor Therapeutics (NASDAQ: CAPR), recognized for developing innovative cell and exosome-based therapies tailored for rare diseases, has exciting news. On November 10, 2025, the company plans to release its financial results for the third quarter, concluding on September 30, 2025. This announcement will take place post-market closure, paving the way for their subsequent webcast and conference call.
Details for the Upcoming Conference Call
Scheduled for 4:30 p.m. ET on the same day, this event invites participants to join the conversation about Capricor's financial performance and strategies moving forward. A toll-free number, 1-800-717-1738, is provided for callers in the U.S., while international participants can dial in at 1-646-307-1865. Make sure to note the conference ID: 13683 for access.
Simple Ways to Join the Webcast
For those unable to attend the call, a seamless joining option is available through a dedicated link that offers instant telephone access to the event. This is designed to ensure that all interested parties can easily participate in this significant update.
Replay Access to the Webcast
After the live session, a replay of the webcast will be made accessible on the company’s official website, allowing investors and stakeholders to review the detailed insights shared during the event.
About Capricor Therapeutics' Innovative Approach
Capricor Therapeutics (NASDAQ: CAPR) remains at the forefront of biotechnology innovation. The company is devoted to enhancing treatment options for rare diseases, with its flagship product candidate, Deramiocel, leading the charge in clinical development targeting Duchenne muscular dystrophy (DMD). This allogeneic cardiac-derived cell therapy showcases impressive immunomodulatory and anti-fibrotic effects, which have been supported by extensive research.
Advancements in Exosome Technology
In addition to Deramiocel, Capricor is pioneering exosome technology through its proprietary StealthX™ platform, which focuses on targeted delivery solutions for vaccines, proteins, and small-molecule therapeutics. This multidimensional approach opens pathways to potentially address a variety of diseases and health challenges.
Commitment to Transformative Healthcare Solutions
At Capricor, the commitment to pushing the boundaries of medical science is palpable. The dedicated team is continuously exploring new avenues in research and development to deliver transformative treatments for patients in need. Engagement with industry partners reinforces their mission, as they aim for groundbreaking advancements in therapeutic solutions.
Connecting with Capricor Therapeutics
For more information about Capricor’s progress and initiatives, interested parties are encouraged to visit their website for updates. The company actively engages with the community through social media channels, including Facebook, Instagram, and X (formerly Twitter), ensuring that stakeholders are informed and connected to their developments.
Frequently Asked Questions
1. What will Capricor be discussing in the upcoming call?
Capricor will discuss its Q3 2025 financial results and recent corporate updates.
2. How can I participate in the Capricor conference call?
You can join the call by using the toll-free number or the international dialing option provided. Don't forget the conference ID: 13683.
3. Where can I find the replay of the webcast?
The replay will be available on Capricor's official website after the live session concludes.
4. What is Deramiocel?
Deramiocel is Capricor’s leading product candidate, a cell therapy targeting Duchenne muscular dystrophy, shown to have significant therapeutic effects.
5. How does Capricor use exosome technology?
Capricor utilizes its proprietary StealthX™ platform to develop targeted delivery systems for various therapeutic applications, aimed at treating multiple diseases.
